[1] Chen S C, Kuo P L. Bone metastasis from renal cell carcinoma[J]. Int J Mol Sci, 2016, 17(6): 987-1004.
[2] Shankar K, Kumar D, Kumar K V, et al. Renal cell carcinoma with unusual skeletal metastasis to tibia and ankle: a case report and review of literature[J]. J Clin Diagn Res, 2016, 10(11): D1-D2.
[3] Du Y, Pahernik S, Hadaschik B, et al. Survival and prognostic factors of patients with renal cell cancer with bone metastasis in the era of targeted therapy: a single-institution analysis[J]. Urol Oncol, 2016, 34(10): 431-433.
[4] 兰 敏, 刘家明, 刘志礼, 等. 肾癌骨转移的相关预测及诊断因素分析[J]. 临床泌尿外科杂志, 2018, 33(1): 36-38.
[5] Casazza A, Laoui D, Wenes M, et al. Impeding macrophage entry into hypoxic tumor areas by Sema 3A/Nrp1 signaling blockade inhibits angiogenesis and restores antitumor immunity[J]. Cancer Cell, 2013, 24(6): 695-709.
[6] Chanmee T, Ontong P, Konno K, et al. Tumor-associated macrophages as major players in the tumor microenvironment[J]. Cancers (Basel), 2014,6(3): 1670-1690.
[7] Atkins M B, Tannir N M. Current and emerging therapies for first-line treatment of metastatic clear cell renal cell carcinoma[J]. Cancer Treat Rev, 2018,70: 127-137.
[8] Irelli A, Cocciolone V, Cannita K, et al. Bone targeted therapy for preventing skeletal-related events in metastatic breast cancer[J]. Bone, 2016,87: 169-175.
[9] Guo Q, Zhang C, Guo X, et al. Incidence of bone metastasis and factors contributing to its development and prognosis in newly diagnosed renal cell carcinoma: a population-based study[J]. Cancer Manag Res, 2018,10: 2935-2944.
[10] Chen X Y, Lan M, Zhou Y, et al. Risk factors for bone metastasis from renal cell cancer[J]. J Bone Oncol, 2017,9: 29-33.
[11] Budak E, Yanarates A. Role of ¹⁸F-FDG PET/CT in the detection of primary malignancy in patients with bone metastasis of unknown origin[J]. Rev Esp Med Nucl Imagen Mol, 2020,39(1): 14-19.
[12] Elahmadawy M A, Elazab M, Ahmed S, et al. Diagnostic value of F-¹⁸FDG PET/CT for local and distant disease relapse surveillance in surgically treated RCC patients: can it aid in establishing consensus follow up strategy?[J]. Nucl Med Rev Cent East Eur, 2018,21(2): 85-91.
[13] Liu Y. The place of FDG PET/CT in renal rell rarcinoma: value and limitations[J]. Front Oncol, 2016,6: 201-208.
[14] 郑飞波, 刘晚霞, 丁月云, 等. 转移性骨肿瘤的影像学诊断进展[J]. 实用医学影像杂志, 2015,16(3): 253-255.
[15] 廖栩鹤, 王荣福, 张建华, 等. 肿瘤正电子显像的临床应用现状与前景[J]. 肿瘤学杂志, 2019,25(4): 364-371.
[16] Ahn T, Roberts M J, Abduljabar A, et al. A review of prostate-specific membrane antigen (PSMA) positron emission tomography (PET) in renal cell carcinoma (RCC)[J]. Mol Imaging Biol, 2019,21(5): 799-807.
[17] 肾癌骨转移专家共识编写组. 肾癌骨转移专家共识(2020版)[J]. 中华肿瘤杂志, 2020,42(7): 537-542.
[18] Fioramonti M, Santini D, Iuliani M, et al. Cabozantinib targets bone microenvironment modulating human osteoclast and osteoblast functions[J]. Oncotarget, 2017, 8(12): 20113-20121.
[19] Escudier B, Powles T, Motzer R J, et al. Cabozantinib, a new standard of care for patients with advanced renal cell carcinoma and bone metastases subgroup analysis of the METEOR trial[J]. J Clin Oncol, 2018, 36(8): 765-772.
[20] Motzer R, Tannir N, Mcdermott D, et al. Nivolumab plus Ipilimumab versus Sunitinib in advanced renal-cell carcinoma[J]. N Engl J Med,2018,378(14):1277-1290.
[21] Escudier B, Sharma P, McDermott D F, et al. CheckMate 025 randomized phase 3 study: outcomes by key baseline factors and prior therapy for Nivolumab versus Everolimus in advanced renal cell carcinoma[J]. Eur Urol, 2017, 72(6): 962-971.
[22] Owari T, Miyake M, Nakai Y, et al. Clinical benefit of early treatment with bone-modifying agents for preventing skeletal-related events in patients with genitourinary cancer with bone metastasis: a multi-institutional retrospective study[J]. Int J Urol, 2019, 26(6): 630-637.
[23] Umer M, Mohib Y, Atif M, et al. Skeletal metastasis in renal cell carcinoma: a review[J]. Ann Med Surg (Lond), 2018, 27: 9-16.
[24] Hu M I, Glezerman I, Leboulleux S, et al. Denosumab for patients with persistent or relapsed hypercalcemia of malignancy despite recent bisphosphonate treatment[J]. J Natl Cancer Inst, 2013,105(18): 1417-1420.
[25] Wong E, Kapoor A. Does bone-targeted therapy benefit patients with metastatic renal cell carcinoma?[J]. Transl Oncol, 2020,13(2): 241-244.
[26] Guillot A, Joly C, Barthelemy P, et al. Denosumab toxicity when combined with anti-angiogenic therapies on patients with metastatic renal cell carcinoma: a GETUG study[J]. Clin Genitourin Cancer, 2019, 17(1): e38-e43.
[27] Taunk N K, Spratt D E, Bilsky M, et al. Spine radiosurgery in the management of renal cell carcinoma metastases[J]. J Natl Compr Canc Netw, 2015, 13(6): 801-809.
[28] Costelloe C M, Chuang H H, Madewell J E, et al. Cancer response criteria and bone metastases: RECIST 1.1, MDA and PERCIST[J]. J Cancer, 2010,1: 80-92.
[29] Hosaka S, Katagiri H, Niwakawa M, et al. Radiotherapy combined with zoledronate can reduce skeletal-related events in renal cell carcinoma patients with bone metastasis[J]. Int J Clin Oncol, 2018, 23(6): 1127-1133.
[30] Amini A, Altoos B, Bourlon M T, et al. Local control rates of metastatic renal cell carcinoma (RCC) to the bone using stereotactic body radiation therapy: is RCC truly radioresistant?[J]. Pract Radiat Oncol, 2015, 5(6): e589-e596.
[31] De Wolf K, Rottey S, Vermaelen K, et al. Combined high dose radiation and pazopanib in metastatic renal cell carcinoma: a phase I dose escalation trial[J]. Radiat Oncol, 2017, 12(1): 157-164.
[32] Negishi T, Furubayashi N, Takamatsu D, et al. Radiographical efficacy of systemic treatment for bone metastasis from renal cell carcinoma[J]. Oncol Lett, 2020, 20(5): 267-272.
[33] Singh R, Ansinelli H, Sharma D, et al. Stereotactic body radiation therapy (SBRT) for metastatic renal cell carcinoma: a multi-institutional experience[J]. J Radiosurg SBRT, 2020, 7(1): 29-37.
[34] Teyssonneau D, Gross-Goupil M, Domblides C, et al. Treatment of spinal metastases in renal cell carcinoma: a critical review[J]. Crit Rev Oncol Hematol, 2018, 125: 19-29.
[35] Gardner C S, Ensor J E, Ahrar K, et al. Cryoablation of bone metastases from renal cell carcinoma for local tumor control[J]. J Bone Joint Surg Am, 2017, 99(22): 1916-1926.
[36] Grunwald V, Eberhardt B, Bex A, et al. An interdisciplinary consensus on the management of bone metastases from renal cell carcinoma[J]. Nat Rev Urol, 2018, 15(8): 511-521.
[37] Griessenauer C J, Salem M, Hendrix P, et al. Preoperative embolization of spinal tumors: a systematic review and meta-analysis[J]. World Neurosurg, 2016,87: 362-371.
[38] Heianna J, Makino W, Ariga T, et al. Concomitant radiotherapy and transarterial chemoembolization reduce skeletal-related events related to bone metastases from renal cell carcinoma[J]. Eur Radiol, 2020, 30(3): 1525-1533.
[39] Laufer I, Rubin D G, Lis E, et al. The NOMS framework: approach to the treatment of spinal metastatic tumors[J]. Oncologist, 2013,18(6): 744-751.
[40] Zaid H B, Parker W P, Safdar N S, et al. Outcomes following complete surgical metastasectomy for patients with metastatic renal cell carcinoma: a systematic review and meta-analysis[J]. J Urol, 2017,197(1): 44-49.
[41] Grunwald V, Eberhardt B, Bex A, et al. An interdisciplinary consensus on the management of bone metastases from renal cell carcinoma[J]. Nat Rev Urol, 2018, 15(8): 511-521.
[42] 魏希姨, 游泽斌, 李光耀, 等. 肾癌骨转移患者的病情评估和治疗策略选择[J]. 中华泌尿外科杂志, 2019,40(11): 833-834.
[43] Kitamura H, Takahashi A, Takei F, et al. Molecular-targeted therapy and surgery may prolong survival of renal cell carcinoma patients with bone metastasis: a multi-institutional retrospective study in Japan[J]. Anticancer Res, 2016, 36(10): 5531-5536.
[44] Tatsui C E, Suki D, Rao G, et al. Factors affecting survival in 267 consecutive patients undergoing surgery for spinal metastasis from renal cell carcinoma[J]. J Neurosurg Spine, 2014, 20(1): 108-116.
[45] Dong Y, Wang Z, Lu X, et al. Clinical outcomes of 168 Chinese patients after local surgery for bone metastases arising from advanced renal cell carcinoma[J]. Cancer, 2020,126(Suppl 9): 2079-2085.
[46] Derosa L, Bayar M A, Albiges L, et al. A new prognostic model for survival in second line for metastatic renal cell carcinoma: development and external validation[J]. Angiogenesis, 2019, 22(3): 383-395.
[47] Owari T, Miyake M, Nakai Y, et al. A genitourinary cancer-specific scoring system for the prediction of survival in patients with bone metastasis: a retrospective analysis of prostate cancer, renal cell carcinoma, and urothelial carcinoma[J]. Anticancer Res, 2018,38(5): 3097-3103.
[48] 王林辉, 董 毅. 重视肾癌骨转移的个体化治疗[J]. 临床泌尿外科杂志, 2018,33(5): 337-341.